Abstract
Malaria and leishmaniasis are the most prevalent tropical diseases caused by protozoan parasites. Half of worlds population is at risk of malaria and more than 2 million of new cases of leishmaniasis occur annually. There are no vaccines available for these diseases and current treatments suffer from several limitations. Therefore, novel drugs for malaria and leishmaniasis are much-needed. This article reviews the agents currently in use for treatment of these diseases, their known mechanisms of action and weaknesses. We present an overview of the main strategies for drug discovery and the relevance of these parasites genomics/proteomics data for a rational search of molecular targets and matching leads. In this direction, we emphasize the importance of the highly integrated partnerships and networks between scientists in academic institutions and industry involving several countries that promise to increase the chances of success and enhance cost-effectiveness in drug discovery against these parasitic diseases. In addition, we approach the available assays for testing lead compounds in large scale and their limitations for they represent one of the bottlenecks in the pipeline for novel drug discovery. We conclude the article presenting a recent coordinated initiative (TDR Transfection Network) established to overcome some of these limitations by the generation of Plasmodium and Leishmania transgenic parasites better suited for HTS platforms.
Keywords: Leishmaniasis, malaria, chemotherapy, drug discovery, molecular targets
Current Drug Targets
Title: Current Treatment and Drug Discovery Against Leishmania spp. and Plasmodium spp.: A Review
Volume: 10 Issue: 3
Author(s): Angela Kaysel Cruz, Juliano Simoes de Toledo, Mofolusho Falade, Monica Cristina Terrao, Sumalee Kamchonwongpaisan, Dennis E. Kyle and Chairat Uthaipibull
Affiliation:
Keywords: Leishmaniasis, malaria, chemotherapy, drug discovery, molecular targets
Abstract: Malaria and leishmaniasis are the most prevalent tropical diseases caused by protozoan parasites. Half of worlds population is at risk of malaria and more than 2 million of new cases of leishmaniasis occur annually. There are no vaccines available for these diseases and current treatments suffer from several limitations. Therefore, novel drugs for malaria and leishmaniasis are much-needed. This article reviews the agents currently in use for treatment of these diseases, their known mechanisms of action and weaknesses. We present an overview of the main strategies for drug discovery and the relevance of these parasites genomics/proteomics data for a rational search of molecular targets and matching leads. In this direction, we emphasize the importance of the highly integrated partnerships and networks between scientists in academic institutions and industry involving several countries that promise to increase the chances of success and enhance cost-effectiveness in drug discovery against these parasitic diseases. In addition, we approach the available assays for testing lead compounds in large scale and their limitations for they represent one of the bottlenecks in the pipeline for novel drug discovery. We conclude the article presenting a recent coordinated initiative (TDR Transfection Network) established to overcome some of these limitations by the generation of Plasmodium and Leishmania transgenic parasites better suited for HTS platforms.
Export Options
About this article
Cite this article as:
Cruz Kaysel Angela, de Toledo Simoes Juliano, Falade Mofolusho, Terrao Cristina Monica, Kamchonwongpaisan Sumalee, Kyle E. Dennis and Uthaipibull Chairat, Current Treatment and Drug Discovery Against Leishmania spp. and Plasmodium spp.: A Review, Current Drug Targets 2009; 10 (3) . https://dx.doi.org/10.2174/138945009787581177
DOI https://dx.doi.org/10.2174/138945009787581177 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design The Impact of Bariatric Surgery in Patients with Type-2 Diabetes Mellitus
Current Diabetes Reviews Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Current Neurovascular Research Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Indane-1,3-diones: As Potential and Selective α-glucosidase Inhibitors, their Synthesis, <i>in vitro</i> and <i>in silico</i> Studies
Medicinal Chemistry Copeptin as a Biomarker in Cardiac Disease
Current Topics in Medicinal Chemistry Obesity- An Adverse Factor in Reproductive Age
Applied Clinical Research, Clinical Trials and Regulatory Affairs Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets Clozapine Safety, 40 Years Later
Current Drug Safety Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Physiologic Versus Diabetogenic Effects of Interleukin-1: A Question of Weight
Current Pharmaceutical Design Hepatocyte Growth Factor and Insulin-like Growth Factor-1 based Cellular Therapies for Oxidative Stress Injury
Current Stem Cell Research & Therapy Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry